Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Rheumatology | Dermatology | Immunology | Family Medicine
Disease Category: Psoriatic Arthritis
Location: United States, MD
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled trial of Ustekinumab, a Fully Human anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Psoriatic Arthritis
Do you have Psoriatic Arthritis? You may qualify to participate in a clinical research study.
Previously approved for the treatment of psoriasis, this agent is now being tested for BOTH biologic naïve as well as biologic exposed patients with psoriatic arthritis with active disease. This trial provides care for 108 weeks for biologic naïve patients and 60 weeks for patients with prior biologic exposure.
CW ID: 170025
Date Last Changed:
July 23, 2013
The Center for Rheumatology and Bone Research2730 University Blvd West, Suite 306Wheaton, MD 20902Phone: 301 942-6610Fax: 301 942-7833
The Center for Rheumatology and Bone Research
If you would like to learn more about participating in this research study, please email the trial contact using the form below.
We value your privacy and your information will only be used by the research center to contact
you regarding this study.
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.
Copyright © 1995-2017 CenterWatch.